Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

• Published in: Clinical cancer research Vol. 15; no. 23; pp. 7381 - 7388
• Main Authors: MITTENDORF, Elizabeth A, YUN WU, HORTOBAGYI, Gabriel N, BASELGA, Jose, GONZALEZ-ANGULO, Ana M, SCALTRITI, Maurizio, MERIC-BERNSTAM, Funda, HUNT, Kelly K, DAWOOD, Shaheenah, ESTEVA, Francisco J, BUZDAR, Aman U, HUIQIN CHEN, EKSAMBI, Sameena
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.12.2009
• Subjects: Adult; Aged; Aged, 80 and over; Anthracyclines - pharmacology; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal, Humanized; Antineoplastic agents; Antineoplastic Agents - pharmacology; Biological and medical sciences; breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - therapy; Cell Line, Tumor; Disease-Free Survival; Female; HER2/neu; Humans; Medical sciences; Middle Aged; neoadjuvant chemotherapy; Neoadjuvant Therapy - methods; Pharmacology. Drug treatments; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Recurrence; Taxoids - metabolism; Trastuzumab; Treatment Outcome; Antineoplastic agent; Gene amplification; Prognosis; C-Onc gene; erbB2 Gene; Monoclonal antibody; Survival; Protooncogene; Neoadjuvant treatment; Trastuzumab; Human Epidermal growth factor Receptor 2

Purpose: To evaluate HER2 status in residual tumor identified at the time of surgery in patients not achieving a pathologic complete response (pCR) and to determine the effect of alterations in HER2 status on recurrence-free survival (RFS). Experimental Design: Clinicopathologic data for patients wi...